
    
      The primary objective of this phase 2 study is to assess objective response rate of SHR-1210
      in patients with R/M NPC. The secondary objective is to observe the duration of response,
      progression free survival, time to response, overall survival and safety of SHR-1210 in R/M
      NPC. ADA is also investigated.
    
  